Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q14896: Variant p.Arg502Gln

Myosin-binding protein C, cardiac-type
Gene: MYBPC3
Feedback?
Variant information Variant position: help 502 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Glutamine (Q) at position 502 (R502Q, p.Arg502Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In CMH4. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 502 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1274 The length of the canonical sequence.
Location on the sequence: help AQVKWLKDGVELTREETFKY R FKKDGQRHHLIINEAMLEDA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1274 Myosin-binding protein C, cardiac-type
Domain 453 – 543 Ig-like C2-type 3
Beta strand 499 – 506



Literature citations
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.
Niimura H.; Bachinski L.L.; Sangwatanaroj S.; Watkins H.; Chudley A.E.; McKenna W.; Kristinsson A.; Roberts R.; Sole M.; Maron B.J.; Seidman J.G.; Seidman C.E.;
N. Engl. J. Med. 338:1248-1257(1998)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS CMH4 GLN-451; GLN-495 AND GLN-502; Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene.
Ehlermann P.; Weichenhan D.; Zehelein J.; Steen H.; Pribe R.; Zeller R.; Lehrke S.; Zugck C.; Ivandic B.T.; Katus H.A.;
BMC Med. Genet. 9:95-95(2008)
Cited for: VARIANTS CMH4 LYS-258; CYS-272; VAL-336; GLN-495; GLN-502; SER-957 AND ILE-958; Shared genetic causes of cardiac hypertrophy in children and adults.
Morita H.; Rehm H.L.; Menesses A.; McDonough B.; Roberts A.E.; Kucherlapati R.; Towbin J.A.; Seidman J.G.; Seidman C.E.;
N. Engl. J. Med. 358:1899-1908(2008)
Cited for: VARIANTS CMH4 GLU-278; ARG-490; GLY-495; GLN-502; TRP-502; ASN-605; SER-1028 AND ARG-1248; VARIANTS MET-158; GLY-236; GLN-326; MET-896 AND TRP-1002;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.